Literature DB >> 33343208

Current locoregional therapies and treatment strategies in hepatocellular carcinoma.

L Cardarelli-Leite1, A Hadjivassiliou2, D Klass2, J Chung2, S G F Ho2, H J Lim3, P T W Kim4, A Mujoomdar1, D M Liu2.   

Abstract

Locoregional therapies (lrts) play an important role in the treatment of hepatocellular carcinoma (hcc), with the aim of increasing overall survival while preserving liver function. Various forms of lrt are available, and choosing the best one depends on technical aspects, liver morphology, tumour biology, and the patient's symptoms. The purpose of the present review article is to provide an overview of the current evidence relating to the use of percutaneous ablation, transarterial chemoembolization, and transarterial radioembolization for the curative or palliative treatment of hcc. Special situations are also reviewed, including the combined use of systemic therapy and lrt, indications and techniques for bridging to transplant and downstaging, and the use of lrt to treat patients with hcc and macrovascular invasion. 2020 Multimed Inc.

Entities:  

Keywords:  Hepatocellular carcinoma; chemoembolization; interventional radiology; radiofrequency ablation; transarterial radioembolization

Year:  2020        PMID: 33343208      PMCID: PMC7739520          DOI: 10.3747/co.27.7171

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  90 in total

1.  Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria.

Authors:  M Ravaioli; G L Grazi; F Piscaglia; F Trevisani; M Cescon; G Ercolani; M Vivarelli; R Golfieri; A D'Errico Grigioni; I Panzini; C Morelli; M Bernardi; L Bolondi; A D Pinna
Journal:  Am J Transplant       Date:  2008-12       Impact factor: 8.086

Review 2.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; María Reig; Jordi Bruix
Journal:  Lancet       Date:  2018-01-05       Impact factor: 79.321

3.  The SIRveNIB and SARAH trials, radioembolization vs. sorafenib in advanced HCC patients: reasons for a failure, and perspectives for the future.

Authors:  Carlo Sposito; Vincenzo Mazzaferro
Journal:  Hepatobiliary Surg Nutr       Date:  2018-12       Impact factor: 7.293

4.  Radiation therapy and the abscopal effect: a concept comes of age.

Authors:  John Ng; Tong Dai
Journal:  Ann Transl Med       Date:  2016-03

5.  Radiation Segmentectomy: Potential Curative Therapy for Early Hepatocellular Carcinoma.

Authors:  Robert J Lewandowski; Ahmed Gabr; Nadine Abouchaleh; Rehan Ali; Ali Al Asadi; Ronald A Mora; Laura Kulik; Daniel Ganger; Kush Desai; Bartley Thornburg; Samdeep Mouli; Ryan Hickey; Juan Carlos Caicedo; Michael Abecassis; Ahsun Riaz; Riad Salem
Journal:  Radiology       Date:  2018-04-24       Impact factor: 11.105

6.  Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.

Authors:  Josep M Llovet; Maria Isabel Real; Xavier Montaña; Ramon Planas; Susana Coll; John Aponte; Carmen Ayuso; Margarita Sala; Jordi Muchart; Ricard Solà; Joan Rodés; Jordi Bruix
Journal:  Lancet       Date:  2002-05-18       Impact factor: 79.321

7.  Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines.

Authors:  Kenichi Takayasu; Shigeki Arii; Masatoshi Kudo; Takafumi Ichida; Osamu Matsui; Namiki Izumi; Yutaka Matsuyama; Michiie Sakamoto; Osamu Nakashima; Yonson Ku; Norihiro Kokudo; Masatoshi Makuuchi
Journal:  J Hepatol       Date:  2011-12-13       Impact factor: 25.083

8.  Nonsurgical management of advanced hepatocellular carcinoma: a clinical practice guideline.

Authors:  B M Meyers; J Knox; R Cosby; J R Beecroft; K K W Chan; N Coburn; J Feld; D Jonker; A Mahmud; J Ringash
Journal:  Curr Oncol       Date:  2020-05-01       Impact factor: 3.677

9.  Percutaneous ethanol injection for hepatocellular carcinoma: 20-year outcome and prognostic factors.

Authors:  Shuichiro Shiina; Ryosuke Tateishi; Masatoshi Imamura; Takuma Teratani; Yukihiro Koike; Shinpei Sato; Shuntaro Obi; Fumihiko Kanai; Naoya Kato; Haruhiko Yoshida; Masao Omata; Kazuhiko Koike
Journal:  Liver Int       Date:  2012-06-19       Impact factor: 5.828

10.  Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.

Authors:  Masatoshi Kudo; Kazuomi Ueshima; Masafumi Ikeda; Takuji Torimura; Nobukazu Tanabe; Hiroshi Aikata; Namiki Izumi; Takahiro Yamasaki; Shunsuke Nojiri; Keisuke Hino; Hidetaka Tsumura; Teiji Kuzuya; Norio Isoda; Kohichiroh Yasui; Hajime Aino; Akio Ido; Naoto Kawabe; Kazuhiko Nakao; Yoshiyuki Wada; Osamu Yokosuka; Kenichi Yoshimura; Takuji Okusaka; Junji Furuse; Norihiro Kokudo; Kiwamu Okita; Philip James Johnson; Yasuaki Arai
Journal:  Gut       Date:  2019-12-04       Impact factor: 23.059

View more
  3 in total

Review 1.  Non-surgical management of advanced hepatocellular carcinoma: A systematic review by Cancer Care Ontario.

Authors:  Brandon M Meyers; Jennifer J Knox; Roxanne Cosby; J R Beecroft; Kelvin Kw Chan; Natalie Coburn; Jordan J Feld; Derek Jonker; Aamer Mahmud; Jolie Ringash
Journal:  Can Liver J       Date:  2021-08-09

Review 2.  Hepatocellular Carcinoma with Gastrointestinal Involvement: A Systematic Review.

Authors:  Cristiana Marinela Urhut; Larisa Daniela Sandulescu; Liliana Streba; Vlad Florin Iovanescu; Sarmis Marian Sandulescu; Suzana Danoiu
Journal:  Diagnostics (Basel)       Date:  2022-05-19

3.  Absent in melanoma 1-like (AIM1L) serves as a novel candidate for overall survival in hepatocellular carcinoma.

Authors:  Wenliang Zhou; Yuan Zhang; Shixi Zhang; Zongguo Yang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.